CP-870,893 + gemcitabine

CP-870,893 + gemcitabine is a combination drug regimen used in investigational cancer therapy, most notably in advanced pancreatic ductal adenocarcinoma. **CP-870,893** is a fully human CD40 agonist monoclonal antibody that activates immune responses by stimulating antigen-presenting cells and triggering pro-inflammatory cytokine release, thereby enhancing antitumor cellular immunity. **Gemcitabine** is a nucleoside analog chemotherapy agent that inhibits DNA synthesis, causing cell death. The combination is designed to synergistically enhance the immune response to tumor antigens released by chemotherapy. Clinical studies indicate that this regimen was well-tolerated, with immune activation, cytokine responses, and preliminary antitumor effects observed in patients with pancreatic cancer.